Conference | Visikol https://visikol.com Advanced Drug Discovery and Bioimaging Services Tue, 25 Oct 2022 15:42:49 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.5 Visikol CEO To Speak at 3rd International Conference Series on 3R’s Research & Progress https://visikol.com/blog/2022/10/25/visikol-ceo-to-speak-at-3rd-international-conference-series-on-3rs-research-progress/ Tue, 25 Oct 2022 15:42:17 +0000 https://visikol.com/?p=18630
Michael Johnson Speaker Profile

Visikol CEO Michael Johnson, Ph.D., will be speaking at The 3rd International Conference Series on 3R’s Research & Progress – Advances in Animal Models and Cutting-Edge Research in Alternatives

Dr. Johnson’s talk will be on “Choosing the Right Liver In Vitro Model” and can be watched on Friday, November 18, 2022.

The post Visikol CEO To Speak at 3rd International Conference Series on 3R’s Research & Progress first appeared on Visikol.]]> Visikol To Exhibit and Present at 2022 SOT https://visikol.com/blog/2022/02/16/visikol-2022-sot/ Wed, 16 Feb 2022 14:00:08 +0000 https://visikol.com/?p=16428
SOT

Visikol to Exhibit and Present at
2022 SOT Annual Meeting in San Diego

Visit Visikol at booth 2018 at the 2022 SOT Annual Meeting in San Diego.

Scheduled Talks:

HUREL Micro Livers for DMPK Studies
March 28, 2022
10:30AM-11:30AM
RM 23A

Session Description:
HUREL Micro Livers are primary hepatocyte co-culture models that are capable of maintaining metabolic and phenotypic stability for up to two months. These models have appeared in over 50 publications and are ideal for evaluating low clearance compounds. 

Precision Cut Liver Slices for use in NASH and DILI Studies
March 29, 2022
09:00 AM-10:00 AM
RM 23A

Session Description:
Visikol has developed a precision cut liver slice model and assay using human tissues to simulate NASH disease progression. The NASH PCLS assay can be executed using CCL4 mice, F0-F1 human livers with TGF-B stimulation or F3-F4 diseased livers. 

The post Visikol To Exhibit and Present at 2022 SOT first appeared on Visikol.]]> Visikol to Present at the 5th Annual Drug Discovery & Development Conference https://visikol.com/blog/2022/02/14/drug-develppment-conference/ Mon, 14 Feb 2022 14:27:40 +0000 https://visikol.com/?p=16408

Labroots Drug Discovery & Development 2022

DrugDiscoveryEvent

Labroots and the Drug Discovery planning committee are pleased to announce the 5th Annual Drug Discovery & Development Virtual Conference. Labroots will host this online-only event on February 23, 2022. The Drug Discovery planning committee will invite speakers from industry and academia to discuss key challenges, new opportunities, and recent successes in the current landscape of drug discovery and development.

Visikol CEO and Co-Founder Dr. Michael Johnson, Ph.D. will present on ‘Identifying the Ideal In Vitro Liver Model for Various Research Applications’

The post Visikol to Present at the 5th Annual Drug Discovery & Development Conference first appeared on Visikol.]]> Visikol to Exhibit at SLAS2022 https://visikol.com/blog/2022/01/05/slas-2022/ Wed, 05 Jan 2022 14:43:49 +0000 https://visikol.com/?p=16249
SLAS

Visikol to Exhibit at
SLAS2022 International Conference and Exhibition in Boston
February 5-9, 2022

Visikol is excited to exhibit at the SLAS2022 International Conference and Exhibition in Boston!

The SLAS2022 Conference’s “scientific program will bring you more than 80 scientific talks spanning nine educational tracks within life sciences, technology and laboratory automation. Sessions will build off of the innovative, life-changing and sometimes surprising discoveries from the last year, including what the lab of the future will look like, building AI into chemistry and lab operations, omics in drug discovery and therapy, pandemic response and much more.”

The post Visikol to Exhibit at SLAS2022 first appeared on Visikol.]]> Visikol to present at SELECTBIO’s December 2021 Conference https://visikol.com/blog/2021/11/08/visikol-selectbio/ Mon, 08 Nov 2021 13:00:20 +0000 https://visikol.com/?p=16031

Visikol’s Director of Drug Discovery, Peter Worthington Ph.D.,
to Present at
SELECTBIO’s 3D-Cell Culture, Organoids, and Organs-on-Chips Conference

Balancing Cost, Throughput and In Vivo Relevancy for In Vitro Liver Studies

Wednesday, 15 December 2021 at 14:00

While we can generate ever more complex advanced cell culture models for use in our in vitro programs, not all research questions require this level of complexity. Through this presentation, Dr. Worthington will discuss how to balance cost, throughput and in vivo relevancy in the context of drug induced liver injury (DILI) and modeling liver disease (NASH, NAFLD). The presentation will review the use cases and applications for 2D cell culture models, 3D spheroid models and ex vivo precision cut tissue slice model

Peter WorthingtonPeter Worthington Ph.D., Director of Drug Discovery, Visikol

Dr. Worthington is the Director of Drug Discovery at Visikol where he oversees the companies advanced cell culture assays and models. Through his time at Visikol, Dr. Worthington has developed several novel 3D cell culture assays and models which the company now leverages to help its clients accelerate their drug discovery and development programs.

The post Visikol to present at SELECTBIO’s December 2021 Conference first appeared on Visikol.]]> 2021 BICO PARTNERSHIP CONFERENCE https://visikol.com/blog/2021/10/01/bico-partnership-conference/ Fri, 01 Oct 2021 18:03:12 +0000 https://visikol.com/?p=15431
BICO Partnership

Join us virtually for an exciting 2-day conference bringing together industry experts and key opinion leaders to celebrate, inspire and create the future of health. Our conference will offer participants the opportunity to learn about new applications, technologies and workflows, and to showcase groundbreaking discoveries.

The post 2021 BICO PARTNERSHIP CONFERENCE first appeared on Visikol.]]>